Citigroup
EWTX icon

Citigroup’s Edgewise Therapeutics EWTX Stock Holding History

Citigroup’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Buy
59,563
+41,046
+222% +$1.42M ﹤0.01% 2791
2026
Q1 		$583K Sell
18,517
-204,777
-92% -$5.91M ﹤0.01% 3455
2025
Q4 		$5.54M Sell
223,294
-315,159
-59% -$6.33M ﹤0.01% 1947
2025
Q3 		$8.73M Sell
538,453
-186,446
-26% -$2.64M ﹤0.01% 1586
2025
Q2 		$9.5M Buy
724,899
+650,592
+876% +$9.38M ﹤0.01% 1403
2025
Q1 		$1.63M Sell
74,307
-4,190
-5% -$110K ﹤0.01% 2887
2024
Q4 		$2.1M Buy
78,497
+2,656
+4% +$84.6K ﹤0.01% 2779
2024
Q3 		$2.02M Buy
75,841
+52,788
+229% +$1.05M ﹤0.01% 2657
2024
Q2 		$415K Sell
23,053
-13,891
-38% -$242K ﹤0.01% 3506
2024
Q1 		$674K Buy
36,944
+29,683
+409% +$472K ﹤0.01% 3346
2023
Q4 		$79.4K Buy
7,261
+6,083
+516% +$42.7K ﹤0.01% 4301
2023
Q3 		$6.75K Sell
1,178
-13,108
-92% -$89.1K ﹤0.01% 4649
2023
Q2 		$111K Buy
14,286
+13,567
+1,887% +$114K ﹤0.01% 4196
2023
Q1 		$4.8K Sell
719
-204
-22% -$1.89K ﹤0.01% 4954
2022
Q4 		$8.25K Sell
923
-141
-13% -$1.32K ﹤0.01% 4903
2022
Q3 		$10K Sell
1,064
-1,949
-65% -$19.7K ﹤0.01% 4984
2022
Q2 		$24K Buy
3,013
+562
+23% +$4.25K ﹤0.01% 4888
2022
Q1 		$24K Sell
2,451
-8,885
-78% -$114K ﹤0.01% 5051
2021
Q4 		$173K Buy
11,336
+9,839
+657% +$177K ﹤0.01% 4432
2021
Q3 		$25K Buy
1,497
+910
+155% +$16.5K ﹤0.01% 5123
2021
Q2 		$13K Buy
+587
New +$16K ﹤0.01% 5533

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's EWTX Position: Q2 2026 in Review

Citigroup increased its Edgewise Therapeutics (EWTX) stake by 222% in Q2 2026, buying an estimated $1.42M and bringing the position to 59,563 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

Citigroup first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $9.5M in Q2 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Citigroup held 59,563 shares of Edgewise Therapeutics worth $2.42M as of Q2 2026.
  • Citigroup bought 41,046 Edgewise Therapeutics shares in Q2 2026, an estimated $1.42M.
  • Edgewise Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2791 holding.
  • Citigroup first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citigroup's Edgewise Therapeutics position peaked at $9.5M in Q2 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.